Skip to main content

Advertisement

SpringerLink
Log in

KSNM60 in Non-thyroidal Radionuclide Therapy: Leaping into the Future

  • Review
  • Published:
Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

This year, the Korean Society of Nuclear Medicine (KSNM) is celebrating its 60th anniversary. Treatment, as well as diagnosis, has played a very important role in the development of nuclear medicine. Since I-131 was used for thyroid therapy in 1959, other radionuclide therapy is still being used, and attempts to use new radionuclide are increasing. In this review, we briefly summarize and introduce the therapies such as radioimmunotherapy, transarterial radioembolization, radionuclide therapy for neuroendocrine tumors, peptide receptor radionuclide therapy, control of metastatic bone pain, radiation synovectomy, radionuclide brachytherapy, alpha particle therapy, and boron neutron capture therapy, which has been being attempted so far in the field of nuclear medicine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data Availability

Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

References

  1. Kang HJ, Lee SS, Kim KM, Choi TH, Cheon GJ, Kim WS, et al. Radioimmunotherapy with 131I-rituximab for patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma(NHL). Asia Pac J Clin Oncol. 2011;7:136–45.

    Article  Google Scholar 

  2. Lee I, Byun BH, Lim I, Kim BI, Choi CW, Kim KM, et al. Comparisons of 131I-rituximab treatment responses in patients with aggressive lymphoma and indolent lymphoma. Ann Nucl Med. 2019;33:881–90.

    Article  CAS  Google Scholar 

  3. Kang HJ, Lee SS, Byun BH, Kim KM, Lim I, Choi CW, et al. Repeated radioimmunotherapy with 131I-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-Hodgkin lymphoma. Cancer Chemother Pharmacol. 2013;71:945–53.

    Article  CAS  Google Scholar 

  4. Shin DY, Byun BH, Kim KM, Kang JH, Lim I, Kim BI, et al. Radioimmunotherapy with 131I-rituximab as consolidation therapy for patients with diffuse large B-cell lymphoma. Cancer Chemother Pharmacol. 2016;78:825–31.

    Article  CAS  Google Scholar 

  5. Seelam SR, Banka VK, Lee YS, Jeong JM. 188Re Labeled liver therapeutic drugs for hepatic carcinoma (HCC). J Radiopharm Mol Probes. 2019;5:26–35.

    Google Scholar 

  6. Lee JT, Kim EK, Won JY, Lee DY, Lee JD, Yoo NC, et al. Experimental and clinical studies on the intraarterial injection of holmium-166 chitosan complex in the treatment of hepatocellular carcinoma. J Korean Radiol Soc. 2001;44:441–51.

    Article  Google Scholar 

  7. Sohn JH, Choi HJ, Lee JT, Lee JD, Kim JH, Yoon YM, et al. Phase II study of transarterial holmium-166-chitosan complex treatment in patients with a single, large hepatocellular carcinoma. Oncology. 2009;76:1–9.

    Article  CAS  Google Scholar 

  8. Kim JK, Han KH, Lee JT, Paik YH, Ahn SH, Lee JD, et al. Long-term clinical outcome of phase iib clinical trial of percutaneous injection with holmium-166/chitosan complex (Milican) for the treatment of small hepatocellular carcinoma. Clin Cancer Res. 2006;12:543–8.

    Article  CAS  Google Scholar 

  9. Kim DY, Park BJ, Kim YH, Han KH, Cho SB, Cho KR, et al. Radioembolization with yttrium-90 resin microspheres in hepatocellular carcinoma: a multicenter prospective study. Am J Clin Oncol. 2015;38:495–501.

    Article  CAS  Google Scholar 

  10. Shehta A, Lee JM, Suh KS, Kim HC, Hong SK, Cho JH, et al. Bridging and downstaging role of trans-arterial radio-embolization for expected small remnant volume before liver resection for hepatocellular carcinoma Ann Hepatobiliary. Pancreat Surg. 2020;24:421–30.

    Google Scholar 

  11. Cho YY, Lee MJ, Kim HC, Chung JW, Kim YH, Gwak GY. Radioembolization is a safe and effective treatment for hepatocellular carcinoma with portal vein thrombosis: a propensity score analysis. PLoS One. 2016;11:e0154986.

    Article  Google Scholar 

  12. Rhee SH, Kim SG, Cho JH, Park JK, Eo JS, Park SY, et al. Semi-quantitative analysis of post-transarterial radioembolization 90Y microsphere positron emission tomography combined with computed tomography (PET/CT) images in advanced liver malignancy: comparison with (99m)Tc macroaggregated albumin (MAA) single photon emission computed tomography (SPECT). Nucl Med Mol Imaging. 2016;50:63–9.

    Article  CAS  Google Scholar 

  13. Kim YC, Kim YH, Um SH, Seo YS, Park EK, Oh SY, et al. Usefulness of bremsstrahlung images after intra-arterial Y-90 resin microphere radioembolization for hepatic tumors. Nucl Med Mol Imaging. 2011;45:59–67.

    Article  Google Scholar 

  14. Kim SH, Won KS, Choi BW, Jo I, Zeon SK, Chung WJ, et al. Usefulness of F-18 FDG PET/CT in the evaluation of early treatment response after interventional therapy for hepatocellular carcinoma. Nucl Med Mol Imaging. 2012;46:102–10.

    Article  CAS  Google Scholar 

  15. Yoon JK, Ryoo BY, Lee CH, Jeong SH, Cheon YK, Choi CW, et al. 131I-MIBG therapy in malignant pheochromocytoma and medullary thyroid carcinoma. Korean J Nucl Med. 1995;29:319–27.

    Google Scholar 

  16. Kim KH, Kim SM, Seo YD. A Discrepancy between 131I-Metaiodobenzylguanidine (131I-MIBG) scintigraphy and 18F-FDG PET/CT after 131I-MIBG therapy in a patient with recurred malignant pheochromocytoma. Nucl Med Mol Imaging. 2009;43:582–7.

    Google Scholar 

  17. Suh JK, Koh KN, Min SY, Kim YS, Kim H, Im HJ, et al. Feasibility and effectiveness of treatment strategy of tandem high-dose chemotherapy and autologous stem cell transplantation in combination with 131I-MIBG therapy for high-risk neuroblastoma. Pediatr Transplant. 2020;24:e13658.

    Article  CAS  Google Scholar 

  18. Lee JW, Lee S, Cho HW, Ma Y, Yoo KH, Sung KW, et al. Incorporation of high-dose 131I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study. J Hematol Oncol. 2017;10:108.

    Article  Google Scholar 

  19. Lee JW, Kang ES, Sung KW, Yi E, Lee SH, Yoo KH, et al. Incorporation of high-dose 131I-metaiodobenzylguanidine treatment into killer immunoglobulin-like receptor/HLA-ligand mismatched haploidentical stem cell transplantation for children with neuroblastoma who failed tandem autologous stem cell transplantation. Pediatr Blood Cancer. 2017;64(6). https://doi.org/10.1002/pbc.26399.

  20. Chung HW, Park JW, Lee EJ, Jung KH, Paik JY, Lee KH. 131I-MIBG targeting of neuroblastoma cells is acutely enhanced by KCl stimulation through the calcium/calmodulin-dependent kinase pathway. Cancer Biother Radiopharm. 2013;28:488–93.

    Article  CAS  Google Scholar 

  21. Lee H, Suh M, Choi H, Ha S, Paeng JC, Cheon GJ, et al. A pan-cancer analysis of the clinical and genetic portraits of somatostatin receptor expressing tumor as a potential target of peptide receptor imaging and therapy. EJNMMI Res. 2020;10:42.

    Article  CAS  Google Scholar 

  22. Lee CH, Lim I, Woo SK, Kim KI, Lee KC, Song K, et al. The feasibility of 64Cu-PSMA I&T PET for prostate cancer. Cancer Biother Radiopharm. 2021. https://doi.org/10.1089/cbr.2020.4189.

    Article  PubMed  Google Scholar 

  23. Suh M, Im HJ, Ryoo HG, Kang KW, Jeong JM, Kumar S, et al. Head to head comparison of 68Ga-NGUL and 68Ga-PSMA-11 in patients with metastatic prostate cancer: a prospective study. J Nucl Med. 2021. https://doi.org/10.2967/jnumed.120.258434.

  24. Kim MH, Kim SG, Kim DW. Dual-labeled prostate-specific membrane antigen (PSMA)-targeting agent for preoperative molecular imaging and fluorescence-guided surgery for prostate cancer. J Labelled Comp Radiopharm. 2021;64:4–13.

    Article  CAS  Google Scholar 

  25. Lee BS, Chu SY, Jung WJ, Jeong HJ, Lee K, Kim MH, et al. 18F-labeled 1,2,3-triazole-linked Glu-urea-Lys-based PSMA ligands have good pharmacokinetic properties for positron emission tomography imaging of prostate cancer. Prostate. 2020;80:1383–93.

    Article  CAS  Google Scholar 

  26. Lee I, Lim I, Byun BH, Kim BI, Choi CW, Woo SK, et al. A microdose clinical trial to evaluate [18F] Florastamin as a positron emission tomography imaging agent in patients with prostate cancer. Eur J Nucl Med Mol Imaging. 2021;48:95–102.

    Article  CAS  Google Scholar 

  27. Chang YS, Jeong JM, Kim BK, Cho JH, Lee DS, Chung JK, et al. Effect of carrier on labeling and biodistribution of Re-188-hydroxyethylidene diphosphonate. Nucl Med Mol Imaging. 2000;34:344–52.

    Google Scholar 

  28. Jeong JM, Lee YJ, Kim YJ, Chang YS, Lee DS, Chung JK, et al. Preparation of rhenium-188-tin colloid as a radiation synovectomy agent and comparison with rhenium-188-sulfur colloid. Appl Radiat Isot. 2000;52:851–5.

    Article  CAS  Google Scholar 

  29. Lee JD, Park KK, Lee M-G, Kim E-H, Rhim KJ, Lee JT, et al. Radionuclide therapy of skin cancers and Bowen’s disease using a specially designed skin patch. J Nucl Med. 1997;38:697–702.

    CAS  PubMed  Google Scholar 

  30. Kim W, Jeong MH, Park OY, Rhew JY, Bom HS, Choi SJ, et al. Effects of beta-radiation using a holmium-166 coated balloon on neointimal hyperplasia in a porcine coronary stent restenosis model. Circ J. 2003;67:625–9.

    Article  Google Scholar 

  31. Kim W, Jeong MH, Kim SH, Park WS, Park OY, Kim JH, et al. A novel method of brachytherapy using local delivery of 99mTc-HMPAO for coronary stent restenosis. Korean J Intern Med. 2004;19:179–88.

    Article  CAS  Google Scholar 

  32. Won JH, Lee JD, Wang HJ, Kim G-E, Kim BW, Yim H, et al. Self-expandable covered metallic esophageal stent impregnated with beta-emitting radionuclide: an experimental study in canine esophagus. Int J Radiat Oncol Biol Phys. 2002;53:1005–13.

    Article  Google Scholar 

  33. Won JH, Lee JD, Wang HJ, Han JH, Kim JH, Kim KH, et al. Effects of a holmium-166 incorporated covered stent placement in normal canine common bile ducts. J Vasc Interv Radiol. 2005;16:705–11.

    Article  Google Scholar 

  34. Shin JH, Song HY, Moon DH, Oh SJ, Kim JS, Kim EH, et al. Effects of irradiation using a radioisotope-filled balloon on tissue hyperplasia caused by stent placement in a canine urethral model. Acta Radiol. 2006;47:436–43.

    Article  Google Scholar 

  35. Kim G, Chun K, Park SH, Kim B. Production of alpha-particle emitting 211At using 45 MeV alpha-beam. Phys Med Biol. 2014;59:2849–60.

    Article  Google Scholar 

  36. Lee T, Kim M, Lee W, Kim B, Lim I, Song K, et al. Performance evaluation of a Compton SPECT imager for determining the position and distribution of 225Ac in targeted alpha therapy: a Monte Carlo simulation based phantom study. Appl Radiat Isot. 2019;154:108893.

    Article  CAS  Google Scholar 

  37. Lee DJ, Han CY, Park SH, Kim JK. An accelerator-based epithermal neutron beam design for BNCT and dosimetric evaluation using a voxel head phantom. Radiat Prot Dosimetry. 2004;110:655–60.

    Article  CAS  Google Scholar 

  38. Kim EH, Rhee CH. A microdosimetric approach to the thermal neutron fluence prescription for clinical BNCT. Radiat Prot Dosimetry. 2004;112:377–83.

    Article  CAS  Google Scholar 

  39. Kim KO, Kim JK, Kim SY. Optimized therapeutic neutron beam for accelerator-based BNCT by analyzing the neutron angular distribution from 7Li(p, n)7Be reaction. Appl Radiat Isot. 2009;67:1173–9.

    Article  CAS  Google Scholar 

  40. Lee E, Lee CW, Cho G. Radiation safety analysis for the A-BNCT facility in Korea. Appl Radiat Isot. 2018;142:92–103.

    Article  CAS  Google Scholar 

  41. Lee W, Sarkar S, Ahn H, Kim JY, Lee YJ, Chang Y, et al. PEGylated liposome encapsulating nido-carborane showed significant tumor suppression in boron neutron capture therapy (BNCT). Biochem Biophys Res Commun. 2020;522:669–75.

    Article  CAS  Google Scholar 

  42. Yoo J, Do Y. Synthesis of stable platinum complexes containing carborane in a carrier group for potential BNCT agents. Dalton Trans. 2009;(25):4978–86.

  43. Jung JY, Lu B, Yoon DK, Hong KJ, Jang H, Liu C, et al. Therapy region monitoring based on PET using 478 keV single prompt gamma ray during BNCT: A Monte Carlo simulation study. Phys Med. 2016;32:562–7.

    Article  Google Scholar 

  44. Yoon DK, Jung JY, Jo Hong K, Sil Lee K, Suk SuhT. GPU-based prompt gamma ray imaging from boron neutron capture therapy. Med Phys. 2015;42:165–9.

    Article  Google Scholar 

Download references

Author information

Author notes

  1. Byung Hyun Byun and Myoung Hyoun Kim contributed equally to this work.

Authors and Affiliations

  1. Department of Nuclear Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences (KIRAMS), Seoul, South Korea

    Byung Hyun Byun

  2. Department of Nuclear Medicine, Institute of Wonkwang Medical Science, Wonkwang University School of Medicine, Iksan, Jeollabuk-do, South Korea

    Myoung Hyoun Kim

  3. Department of Nuclear Medicine, Research Institute of Clinical Medicine of Jeonbuk National University and Biomedical Research Institute of Jeonbuk National University Hospital, 20, Geonji-ro, Duckjin-gu, Jeonju-si, Jeollabuk-do, 561-803, South Korea

    Yeon-Hee Han & Hwan-Jeong Jeong

Authors
  1. Byung Hyun Byun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Myoung Hyoun Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yeon-Hee Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hwan-Jeong Jeong
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Byung Hyun Byun and Myoung Hyoun Kim: historical data collection and analyses and primary writing. Yeon-Hee Han: data review and curation and editing. Hwan-Jeong Jeong: data review and approval and critical manuscript revisions.

Corresponding author

Correspondence to Hwan-Jeong Jeong.

Ethics declarations

Ethics Approval and Consent to Participate

This work does not contain any studies with human participants or animals performed by any of the authors.

Consent for Publication

Not applicable.

Competing Interests

Byung Hyun Byun, Myoung Hyoun Kim, Yeon-Hee Han, and Hwan-Jeong Jeong declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Byun, B.H., Kim, M.H., Han, YH. et al. KSNM60 in Non-thyroidal Radionuclide Therapy: Leaping into the Future. Nucl Med Mol Imaging 55, 203–209 (2021). https://doi.org/10.1007/s13139-021-00703-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13139-021-00703-9

Keywords

Search

Navigation